College of Pharmacy Logo
College of Pharmacy Program Awarded $34M Contra Renewal to Test and Identify Investigational Therapeutics that Prevent and Treat Drug-Resistant Epilepsy
.jpg)
The University of Utah College of Pharmacy’s Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $34 million contract renewal with the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) to test and identify novel investigational therapeutics for preventing the development of epilepsy and treating refractory, or drug-resistant, epilepsy.
Congratulations to all involved!